Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

doi:10.12998/wjcc.v10.i12.3698

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3191)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-7) series.

Item

Count

PDF

205

WORD

HTML

1696

Figures (1-2)

253

Tables (1-7)

261

Sum=2479

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

207

Download

505

Sum=712

Apr 26, 2022 (publication date) through Aug 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Apr 26, 2022; 10(12): 3698-3708
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3698

Table 7 Multivariate analysis of the prognosis of triple-negative breast cancer

Factors		SE	Walds	P value	RR (95%CI)
TNM staging	0.454	0.102	19.811	0.000	1.575 (1.289-1.923)
Degree of differentiation	0.322	0.104	9.586	0.000	1.380 (1.125-1.692)
Lymph node metastasis	0.312	0.112	7.760	0.000	1.366 (1.097-1.702)
KPNA2	0.360	0.121	8.852	0.000	1.433 (1.131-1.817)
SOX2	0.344	0.132	6.792	0.000	1.411 (1.089-1.827)
Chemotherapy regimens	-0.543	0.142	14.623	0.000	0.581 (0.440-0.767)

KPNA2: Karyopherin A2; SOX2: SRY-related HMG box-2; TNM: Tumor-node-metastasis; RR: Relative risk.

Citation: Ding F, Chen RY, Hou J, Guo J, Dong TY. Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer. World J Clin Cases 2022; 10(12): 3698-3708
URL: https://www.wjgnet.com/2307-8960/full/v10/i12/3698.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i12.3698